
AI is increasingly being used in drug discovery to reduce the time and cost of developing new pharmaceuticals. By using AI for predictive design, companies can virtually create and test drug candidates, potentially improving success rates. However, the effectiveness of AI depends on access to comprehensive data, including often-overlooked negative results. The future of drug discovery may involve fully autonomous labs, which could further enhance efficiency and success in bringing new drugs to market.
Read originalETH Zurich students have engineered what they claim to be the first Swiss humanoid robot, marking a notable achievement in the country's robotics sector. This project exemplifies the innovative spirit and technical expertise of Swiss engineering students. The team is now actively seeking funding to further develop and potentially commercialize their humanoid creation. This endeavor not only showcases the students' capabilities but also positions Switzerland as an emerging contender in the global robotics arena.
© MIT News AIMIT researchers have introduced a novel technique that enhances generative AI models' ability to meet strict safety and task-specific requirements without compromising output quality. By allowing models more freedom during the generation process and enforcing constraints only on the final output, this method, called HardFlow, improves solution quality in high-stakes applications like robotics and computer vision. This approach is particularly significant as it can be applied to existing pretrained models without the need for retraining, making it a versatile tool for safety-critical environments. The development marks a step forward in ensuring AI can be safely and effectively deployed in real-world scenarios where precision is paramount.